Foresight Diagnostics develops the Foresight CLARITY™ liquid biopsy MRD testing platform, an ultrasensitive assay based on PhasED‑Seq that reports detection limits in parts per million. The platform lowers sequencing error by requiring concordant detection of multiple non‑reference events in a single DNA molecule to distinguish tumor ctDNA from healthy cfDNA. Foresight operates a CLIA‑registered laboratory and has invested in automation and a new laboratory in Boulder to scale operations. The company is advancing evidence generation in lymphoma and solid tumors and has initiated the prospective Phase 2 ALPHA3 trial in partnership with Allogene Therapeutics using its CLARITY IUO test. PhasED‑Seq recently received an IDE approval from the U.S. FDA for investigational use in that study. To date, Foresight has raised $86 million in venture financing. Foresight Diagnostics develops a liquid biopsy testing platform, PhasED-Seq, for measurement of minimal residual disease to inform treatment decisions for solid tumors and hematologic malignancies. The company operates a CLIA-registered laboratory and positions its tests to provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches. Led by CEO Jake Chabon, Foresight intends to use the new funding to accelerate clinical development and commercialization of its cancer recurrence testing platform, PhasED-Seq. The company raised $58.75M in a Series B financing to support those efforts. Uplaksh Kumar, Ph.D., will join the company's board of directors as part of the financing. The company is based in Aurora, CO.

Total raised

$92M

Funding rounds

2

Latest round

Series B

Latest activity

Jul 2024